GNS Healthcare and Biogen Idec published results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies. The study resulted in an experimental and computational approach for researchers to integrate clinical, molecular and genetic data into models of disease progression and drug response. This approach helped predict individual patients’ clinical responses to the shutting down of specific path...